ANI Pharmaceuticals (NASDAQ: ANIP ) is the biotech of the week on the Fool's weekly show Biotech Banter. Watch the following video, where senior biotech specialist Brian Orelli and health-care bureau chief Max Macaluso discuss the generic-drug company that went public last year through a merger with BioSante.
Since then the company acquired some already-approved generic drugs from Teva Pharmaceuticals (NYSE: TEVA ) and set up partnerships with Sofgen Pharmaceuticals and Sterling Pharmaceutical Services.
In addition to sales of its generic-drug products, ANI Pharmaceuticals has potential for milestones and royalties from BioSante's legacy programs: a testosterone gel licensed to Teva and a portfolio of cancer vaccines licensed to Aduro BioTech.
The small generic-drug maker might have trouble competing with Teva, Novartis (NYSE: NVS ) , and the rest of the big boys, but ANI Pharmaceuticals may be able to find a niche and potentially be a takeout target down the road.
The generic-drug industry might be boring, but these industries are set up for incredible growth
Uncover David Gardner's scientific approach to crushing the market and his carefully chosen six picks for ultimate growth instantly in this this premium report he's making free for you today. Click here now for access.